Table 1.

Distribution of breast cancer by age, race/ethnicity, tumor characteristics, treatment and comorbidity.

Characteristics	Total		Comorbidity severity								p-Value
			None		Mild		Moderate		Severe
	Count	%	Count	%	Count	%	Count	%	Count	%
	5852	100.0	2499	42.7	2508	42.9	619	10.6	226	3.9
Age at diagnosis (yrs)											<0.001
< 70	4459	76.2	2210	88.4	1708	68.1	428	69.1	113	50.0
70+	1393	23.8	289	11.6	800	31.9	191	30.9	113	50.0
Race/ethnicity											<0.001
Non-hispanic Whites	3400	58.1	1507	60.3	1430	57.0	337	54.4	126	55.8
Non-hispanic Blacks	1602	27.4	534	21.4	762	30.4	221	35.7	85	37.6
AI/AN	53	0.9	24	1.0	18	0.7	9	1.5	2	0.9
API	306	5.2	166	6.6	122	4.9	14	2.3	4	1.8
Hispanic	491	8.4	268	10.7	176	7.0	38	6.1	9	4.0
Tumor size (cm)
< 1.0	994	17.0	402	16.1	463	18.5	95	15.4	34	15.0	0.004
1.0–2.9	3494	59.7	1503	60.1	1510	60.2	354	57.2	127	56.2
≥ 3.0	1364	23.3	594	23.8	535	21.3	170	27.5	65	28.8
Regional lymph node											0.020
pN0	3969	67.8	1691	67.7	1742	69.5	389	62.8	147	65.0
PN1(0.2–2.0 mm)	1127	19.3	489	19.6	468	18.7	127	20.5	43	19.0
pN (> 2.0 mm)	756	12.9	319	12.8	298	11.9	103	16.6	36	15.9
Grade											0.025
Well differentiated	1023	17.5	418	16.7	457	18.2	111	17.9	37	16.4
Moderate differentiated	2286	39.1	963	38.5	1007	40.2	238	38.5	78	34.5
Poorly/undifferentiated	2280	39.0	1010	40.4	915	36.5	253	40.9	102	45.1
Unknown	263	4.5	108	4.3	129	5.1	17	2.8	9	4.0
Hormone receptora											0.170
ER+ and/or PR+	4409	75.3	1861	74.5	1905	76.0	481	77.7	162	71.7
ER− and PR−	1443	24.7	638	25.5	603	24.0	138	22.3	64	28.3
HER2 statusb											0.106
Positive	927	15.8	423	16.9	381	15.2	104	16.8	19	8.4
Negative	3907	66.8	1645	65.8	1693	67.5	410	66.2	159	70.4
Equivocal	243	4.2	105	4.2	99	4.0	26	4.2	13	5.8
Unknown	775	13.2	326	13.1	335	13.4	79	12.8	35	15.5
Local therapy											<0.001
Mastectomy	2708	46.3	1151	46.0	1152	45.9	296	47.8	109	48.2
Lumpectomy + radiation	2690	46.0	1179	47.2	1165	46.5	264	42.7	82	36.3
Lumpectomy, no radiation	454	7.8	169	6.8	191	7.6	59	9.5	35	15.5
Chemotherapy											<0.001
Not indicated by guideline	1103	18.8	427	17.1	518	20.7	116	18.7	42	18.6
Received by guideline	2906	49.7	1430	57.2	1122	44.7	287	46.4	67	29.7
Under treated	1843	31.5	642	25.7	868	34.6	216	34.9	117	51.8
Endocrine therapy											0.217
Not indicated by guideline	1443	24.7	638	25.5	603	24.0	138	22.3	64	28.3
Received by guideline	3277	56.0	1395	55.8	1401	55.9	367	59.3	114	50.4
Under treated	1132	19.3	466	18.7	504	20.1	114	18.4	48	21.2

AI/AN = American Indian/Alaska Native.

API = Asian or Pacific Islander.

ER = Estrogen receptor.

PR = Progesterone receptor.

HER = Human epidermal growth factor receptor 2.

^aBorderline ER or PR was included in the ER+ and/or PR+ group.

^bHer2 positive [3+ by immunohistochemistry (IHC) or amplified by fluorescent in-situ hybridization (FISH)], negative (0, 1+ or 2+ by IHC and not amplified by FISH).